alexa European Medicines Agency Regulations Do Not Mirror FDA’s
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutical Regulatory Affairs: Open Access

Author(s): Gidron M

Abstract Share this page

Awareness of drug safety issues has risen to unprecedented levels in light of some of the drug recalls and adverse events that have occurred in recent years. The result has been new legislation, stricter regulations and revised company strategies in Europe and the U.S. These trends have led to greater regulatory uniformity in the EU, which means greater challenges for the pharmaceutical industry. A company can look forward to improved reporting and an overall enhancement of the quality of the EU regulatory system. If there is a lesson to be learned from recent industry crises, it is that bad things can happen to the best companies. When bad things happen, companies need to have a system in place that will take them through the crisis, including a good communication plan. That includes increasing their understanding of the European Medicines Agency (EMEA) and how the EU system operates. As is often the case when working with governments, education is a key factor, so this issue of The Food & Drug Letter focuses on drug safety in the EU.

  • To read the full article Visit
  • Open Access
This article was published in Food Drug Lett and referenced in Pharmaceutical Regulatory Affairs: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version